SPRY1

Across TCGA pan-cancer cohorts, SPRY1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPRY1 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SPRY1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPRY1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where SPRY1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.468	0.971	<.001	35	view →
CCRCC	DFS	Tertile	II,III,IV	0.464	0.905	.010	8	view →
HNSC	DFS	Quartile	IV	1.000	0.596	.040	8	view →
LUAD	DFS	Median	II,III,IV	0.723	0.914	.008	5	view →
GBM	OS	Tertile	All	0.725	0.923	.018	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPRY1–PDAC (DFS)

Open the PDAC breakdown →